生物学的治療薬の世界市場2018-2022

◆英語タイトル:Global Biologic Therapeutics Market 2018-2022
◆商品コード:IRTNTR21669
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月19日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、生物学的治療薬の世界市場について調査・分析し、市場概要、市場環境、生物学的治療薬市場規模、治療薬種類別(モノクローナル抗体、その他、ワクチン、細胞・組織療法、遺伝子療法)分析、用途別(腫瘍、自己免疫疾患・炎症性疾患、血液疾患、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・生物学的治療薬の世界市場概要
・生物学的治療薬の世界市場環境
・生物学的治療薬の世界市場動向
・生物学的治療薬の世界市場規模
・生物学的治療薬の世界市場:業界構造分析
・生物学的治療薬の世界市場:治療薬種類別(モノクローナル抗体、その他、ワクチン、細胞・組織療法、遺伝子療法)
・生物学的治療薬の世界市場:用途別(腫瘍、自己免疫疾患・炎症性疾患、血液疾患、その他)
・生物学的治療薬の世界市場:地域別市場規模・分析
・生物学的治療薬の北米市場規模・予測
・生物学的治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・生物学的治療薬のアジア太平洋市場規模・予測
・生物学的治療薬の主要国分析
・生物学的治療薬の世界市場:意思決定フレームワーク
・生物学的治療薬の世界市場:成長要因、課題
・生物学的治療薬の世界市場:競争環境
・生物学的治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、AbbVie、Johnson & Johnson、Merck、Pfizerなどです。
【レポートの概要】

About this market
Increasing incidence of chronic diseases and immunological disorders to drive growth in the market. Biologics are ideal for the treatment of chronic disorders including cancer, autoimmune disorders, hormonal deficiencies, neurological disorders, and other critical conditions. The incidence of these diseases is rising significantly in developed nations. The increase in aging population and the lifestyle of people in these countries is responsible for the rise in occurrence of cancer, immunological disorders, and other chronic ailments. Technavio’ s analysts have predicted that the biologic therapeutics market will register a CAGR of over11% by 2022.
Market Overview
Increasing investment in development of biologics
Biotechnological products help manufacturers to earn huge revenues because of the therapeutic benefits they provide. Thus, many pharmaceutical companies are moving toward the development of biologics.
Reimbursement challenges of new biologics
The reimbursements available for biologics are very limited compared with that available for conventional therapeutics, despite the high costs. Manufacturers are providing biologics with mandatory companion diagnostics, which increases the overall cost of that biologic, making it difficult for insurers to provide reimbursements.
For the detailed list of factors that will drive and challenge the growth of the biologic therapeutics market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the increasing incidence of chronic diseases and immunological disorders and the increasing investment in development of biologics, will provide considerable growth opportunities to biologic therapeutics manufactures. AbbVie, Johnson & Johnson, Merck, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF THERAPEUTIC AGENT
• Segmentation by therapeutic agent
• Comparison by therapeutic agent
• Monoclonal antibodies – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Vaccines – Market size and forecast 2017-2022
• Cell and tissue-based therapy – Market size and forecast 2017-2022
• Gene therapy – Market size and forecast 2017-2022
• Market opportunity by therapeutic agent
PART 09: MARKET SEGMENTATION BY APPLICATION
• Oncology
• Autoimmune and inflammatory diseases
• Hematology
• Others
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Johnson & Johnson
• Merck
• Pfizer
PART 17: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global biologic therapeutics market: Segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Biologics in pipeline 2017-2018
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Global biologic therapeutics market – Market share by therapeutic agent 2017-2022 (%)
Exhibit 20: Comparison by therapeutic agent
Exhibit 21: Monoclonal antibodies – Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Sales of major monoclonal antibodies 2015-2017
Exhibit 23: Monoclonal antibodies – Year-over-year growth 2018-2022 (%)
Exhibit 24: Others – Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Others – Year-over-year growth 2018-2022 (%)
Exhibit 26: Vaccines – Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Vaccines – Year-over-year growth 2018-2022 (%)
Exhibit 28: Cell and tissue-based therapy – Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Cell and tissue-based therapy – Year-over-year growth 2018-2022 (%)
Exhibit 30: Gene therapy– Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Gene therapy– Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by type of therapeutic agent
Exhibit 33: Sales of biologics used in oncology 2015-2017 ($ millions)
Exhibit 34: Customer landscape
Exhibit 35: Global biologic therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top three countries in Americas
Exhibit 40: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 41: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 42: Top three countries in EMEA
Exhibit 43: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 44: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 45: Top three countries in APAC
Exhibit 46: Market opportunity
Exhibit 47: Treatment costs of some recently approved biologics in US
Exhibit 48: Patent expiration dates of some biologics
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie overview
Exhibit 54: AbbVie – Business segments
Exhibit 55: AbbVie – Organizational developments
Exhibit 56: AbbVie – Geographic focus
Exhibit 57: AbbVie – Key offerings
Exhibit 58: Johnson & Johnson overview
Exhibit 59: Johnson & Johnson – Business segments
Exhibit 60: Johnson & Johnson – Organizational developments
Exhibit 61: Johnson & Johnson Geographic focus
Exhibit 62: Johnson & Johnson – Segment focus
Exhibit 63: Johnson & Johnson – Key offerings
Exhibit 64: Merck overview
Exhibit 65: Merck – Business segments
Exhibit 66: Merck – Organizational developments
Exhibit 67: Merck – Geographic focus
Exhibit 68: Merck – Segment focus
Exhibit 69: Merck – Key offerings
Exhibit 70: Pfizer overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings




【掲載企業】

AbbVie、Johnson & Johnson、Merck、Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[生物学的治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆